Get the Stockscreener App
0.3358
2.91%
-0.0042
After Hours:
.33
-0.0058
-1.73%
Eterna Therapeutics Inc stock is traded at $0.3358, with a volume of 552.48K.
It is down -2.91% in the last 24 hours and down -0.99% over the past month.
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
See More
Previous Close:
$0.34
Open:
$0.3382
24h Volume:
552.48K
Relative Volume:
0.05
Market Cap:
$16.87M
Revenue:
$598.00K
Net Income/Loss:
$-44.93M
P/E Ratio:
-0.0404
EPS:
-8.31
Net Cash Flow:
$-17.32M
1W Performance:
-12.76%
1M Performance:
-0.99%
6M Performance:
-80.72%
1Y Performance:
-79.30%
1-Day Range:
$0.32
$0.3666
1-Week Range:
$0.312
$0.37
52-Week Range:
$0.2212
$2.625
Eterna Therapeutics Inc Stock (ERNA) Company Profile
Name
Eterna Therapeutics Inc
Sector
Industry
Phone
(212) 582-1199
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Eterna Therapeutics Inc
|
0.3358 | 16.87M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eterna Therapeutics Inc Stock (ERNA) Latest News
ERNA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Eterna Therapeutics Inc (ERNA) is a good investment, but the stock may be undervalued - US Post News
Contrasting Eterna Therapeutics (NASDAQ:ERNA) and Anixa Biosciences (NASDAQ:ANIX) - Defense World
Market Insight: Eterna Therapeutics Inc (ERNA)’s Notable Drop, Closing at 0.36 - The Dwinnex
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Eterna Therapeutics expands scientific board with oncology experts - MSN
Eterna Therapeutics’ Shares Surge After Promising Preclinical Results for ERNA-101 Cell Therapy - HPBL
Eterna Therapeutics expands scientific board with oncology experts By Investing.com - Investing.com Canada
Eterna Therapeutics Announces Expansion of Scientific Advisory Board - GlobeNewswire
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
3 Penny Stocks to Watch Now, 1/16/25 - TipRanks
What Did We Note About Insider Trading At Meiwu Technology Company Ltd (NASDAQ: WNW)? - Stocks Register
ERNA-101 extends survival in mice with ovarian cancer - BioWorld Online
Stock market news: Eterna Therapeutics posted gain of 100.87% while Phio Pharmaceuticals saw loss of 50.44% during mid day trading - Business Upturn
Wall Street Climbs as Producer Inflation Report Offers Relief to Investors – Market - HPBL
Stock market today: Eterna Therapeutics gain over 136.63% while Phio Pharmaceuticals plunged by 40.25% in early trading - Business Upturn
Eterna Therapeutics reports breakthrough in ovarian cancer treatment - Investing.com
Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites - The Manila Times
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer - Yahoo Finance
Eterna Therapeutics faces Nasdaq delisting over market value - Investing.com
Eterna Therapeutics Faces Nasdaq Compliance and Board Changes - TipRanks
Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer - The Manila Times
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors - Yahoo Finance
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com - Defense World
Growth Trends in the Induced Pluripotent Stem Cells (iPSCs) Market, 2024-2035: A Forecasted $5.6 Billion Landscape - GlobeNewswire
Eterna Therapeutics Inc. Announces Appointment of Dr. Elena Ratner to Board of Directors - Marketscreener.com
Eterna Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Eterna Therapeutics faces Nasdaq delisting over share price - Investing.com India
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - Defense World
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - Defense World
ERNA stock touches 52-week low at $0.27 amid market challenges - Investing.com Canada
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - Yahoo Finance
Factor Bioscience and Eterna Therapeutics Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - The Eastern Progress Online
Eterna’s ERNA-101 to be studied in ovarian and breast cancer models - BioWorld Online
Eterna Therapeutics to test cancer cell therapy with MD Anderson By Investing.com - Investing.com Canada
Eterna Therapeutics Launches Research to Evaluate its Lead - GlobeNewswire
Eterna Therapeutics Partners with MD Anderson to Advance Cancer Cell Therapy Research - StockTitan
ERNA stock touches 52-week low at $0.4 amid market challenges - Investing.com Australia
Eterna Therapeutics initiates $1 million stock buyback By Investing.com - Investing.com South Africa
Eterna Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):